United States: Breaking Through To Business Solutions For Personalized Medicine: A Thought-Provoking, Can’t-Miss Industry Event
Last Updated: September 14 2015

Just as with patient treatments, one size does not fit all when it comes to companies involved in personalized medicine. Each is unique in its mission, culture, and capabilities, so it should come as no surprise that each demands a distinct business strategy that can evolve alongside the industry. The annual Business of Personalized Medicine Summit is centered around helping attendees build just that.

While other forums for discussing personalized medicine have, for the most part, focused on relatively specialized areas such as underlying technologies, financing, regulatory pathways, or payment issues, the Summit seamlessly integrates thought leadership and networking into a one-day, one-of-a-kind forum that addresses cross-sections of such issues with a clear eye toward helping attendees build successful, sustainable industry business models.

And because the Summit is a must for all entities who are currently engaged in personalized medicine as well as those seeking to enter the space, it provides the perfect opportunity to connect with key players in this rapidly developing field. Through fresh discussions with key opinion leaders and each other, attendees can collect insights and arrive at solutions that will drive their individual growth and performance within personalized medicine as well as impact the overall future of health care.

The 2015 Summit, co-hosted by Foley & Lardner LLP, the Personalized Medicine Coalition, AmerisourceBergen, and the California Life Sciences Association, will take place on Wednesday, October 7, at the South San Francisco Conference Center in South San Francisco, California, the birthplace of biotechnology.

Who Should Attend

  • Business, legal, and health care professionals interested in industry leaders' real-world experience on the current state of personalized medicine and where growth and opportunity exist
  • Business, legal, and health care professionals interested in discussions regarding the regulatory framework for diagnostics and targeted therapies
  • Executives and entrepreneurs interested in hearing diverse perspectives on both the development and delivery of personalized medicine therapies
  • Payors interested in current status and future possibilities regarding reimbursement of personalized medicine technologies
  • Corporate counsel in life sciences and health care provider organizations
  • Health care professionals working in the field of personalized medicine
  • Health care and life sciences investors
  • Researchers and academic personnel
  • Non-profit organizations

Featured Topics

  • Financing & Venture Capital: How investments, partnerships, and other transactions are impacting the business of personalized medicine
  • Payment: Strategies for identifying your target market, collecting evidence, and getting paid
  • FDA/Regulatory: The FDA's proposed oversight of LDT's, Obama's Precision Medicine Initiative, and what to expect in the future as a result
  • Big Pharma: A look at the industry's involvement and investment in personalized medicine
  • Intellectual Property: High-profile cases with significant implications in the personalized medicine space both at the R&D stage and downstream
  • Big Data: Driving development through complex bioinformatics and collaborative results analysis, plus a look at cybersecurity implications
  • Disruptive Innovation: How personalized medicine is being reshaped through innovative business models, technology applications, and information management
  • Clinical Adoption: Barriers to and solutions for effective understanding, acceptance, integration, and knowledge sharing throughout the personalized medicine life cycle

Register now to hear how some of the industry's best and brightest are tackling today's business challenges and what they envision for the future of personalized medicine. Plus, enjoy a special closing keynote presentation with John Parise, Director & Associate General Counsel at Genentech, and Steven Kafka, PhD, President & Chief Operating Officer at Foundation Medicine, as they highlight Roche's $1 billion majority stake in the genomic cancer diagnostics firm.

For a complete speaker roster and program agenda, visit personalizedmedicinesummit.com.

Questions? Email BPMSummit@forumsmeetings.com or call 303.856.7018.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Lauren Loew
By Jay Varon, Jennifer Keas
By Craig Fochler
By Kathleen Wegrzyn
By Thomas Shriner, Jr.
By Michael Leffel, Irina Kashcheyeva
By Jonathan Israel
By Christopher Donovan, C. Frederick Geilfuss II
By Lucia Muntean, Courtenay Brinckerhoff
By Gregory Husisian
Font Size: